None listed
Conditions
Interventions
Drug : If you agree to participate in this clinical trial, you will be able to gather your basic information and participate in this clinical trial if it meets your criteria for selection and exclusio
Sponsors
Gyeongsang National University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. 19 + at the time of screening 2. A study subject who uses durogesic patch more than 12 mcg as a pain in cancer cells, which has been confirmed systematically 3. The study participants with a numerical evaluation grade 4 or less of the average pain severity 4. A person who has sufficient communication with the clinician about his or her pain 5. Participants who understand the purpose of the study and who have written consent
Exclusion criteria
Exclusion criteria: 1. Subjects with a breakthrough pain greater than or equal to a numeric rating of 5 and a frequency of more than 4 times a day 2. Subjects with delirium 3. The components of Fentanyl, the hypersensitivity reaction to other adipose drugs, and the study subjects 4. Those who have no experience in administering narcotics or have no resistance to narcotics 5. Subjects who had organic impairment or damage such as increased intracranial pressure, consciousness disorder, and coma 6. Participants in research on severe chronic closed diseases 7. Subject to an asthma attack persistence study 8. Subjects with paralytic ileus 9. Person subject to research within 2 weeks of administration or withdrawal of administration of MAO inhibitor
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluation of satisfaction with Matrifen vs. Durogesic | — |
Secondary
| Measure | Time frame |
|---|---|
| End-of-dose failure frequency between two drugs;Attachment force evaluation;Number and intensity of Sudden pain;Evaluation of preference between two drugs | — |
Countries
Korea, Republic of
Contacts
Public ContactJung Hun Kang
Gyeongsang National University Hospital
Outcome results
None listed